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Abstract
Human respiratory syncytial virus (HRSV) and Streptococcus pneumoniae are important
causative agents of respiratory tract infections. Both pathogens are associated with season-
al disease outbreaks in the pediatric population, and can often be detected simultaneously
in infants hospitalized with bronchiolitis or pneumonia. It has been described that respiratory
virus infections may predispose for bacterial superinfections, resulting in severe disease.
However, studies on the influence of bacterial colonization of the upper respiratory tract on
the pathogenesis of subsequent respiratory virus infections are scarce. Here, we have in-
vestigated whether pneumococcal colonization enhances subsequent HRSV infection. We
used a newly generated recombinant subgroup B HRSV strain that expresses enhanced
green fluorescent protein and pneumococcal isolates obtained from healthy children in dis-
ease-relevant in vitro and in vivomodel systems. Three pneumococcal strains specifically
enhanced in vitro HRSV infection of primary well-differentiated normal human bronchial epi-
thelial cells grown at air-liquid interface, whereas two other strains did not. Since previous
studies reported that bacterial neuraminidase enhanced HRSV infection in vitro, we mea-
sured pneumococcal neuraminidase activity in these cultures but found no correlation with
the observed infection enhancement in our model. Subsequently, a selection of pneumo-
coccal strains was used to induce nasal colonization of cotton rats, the best available small
animal model for HRSV. Intranasal HRSV infection three days later resulted in strain-specif-
ic enhancement of HRSV replication in vivo. One S. pneumoniae strain enhanced HRSV
both in vitro and in vivo, and was also associated with enhanced syncytium formation in
vivo. However, neither pneumococci nor HRSV were found to spread from the upper to the
lower respiratory tract, and neither pathogen was transmitted to naive cage mates by direct
contact. These results demonstrate that pneumococcal colonization can enhance subse-
quent HRSV infection, and provide tools for additional mechanistic and intervention studies.
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Introduction
Respiratory tract infections cause a significant global burden of morbidity and mortality in all
age groups. In 2011, the World Health Organization estimated that 1.3 million global deaths
were due to acute respiratory infections, of which the majority occurred in developing coun-
tries in children under 5 years of age [1]. Of all respiratory pathogens S. pneumoniae or pneu-
mococcus is the leading cause of death, accounting for more than 30% of the cases [1]. Many
healthy children and adults carry pneumococci in their upper respiratory tract (URT) and S.
pneumoniae colonizes the nasopharynx of up to 45% of children under 3 years of age and up to
20% of adults [2]. Colonization is a prerequisite for subsequent spread, which may result in re-
spiratory tract infection (sinusitis, otitis media, pneumonia), meningitis or sepsis [3]. More
than 90 S. pneumoniae serotypes have been identified, and pneumococcal vaccines have been
developed containing antigens of up to 23 of the most important serotypes associated with
human disease [4].
Human respiratory syncytial virus (HRSV) is a leading viral cause of respiratory tract infec-
tion in young infants [5]. HRSV is a member of the family Paramyxoviridae, a group of envel-
oped viruses with a single stranded RNA genome of negative polarity [6]. Despite the huge
global burden of HRSV disease, no licensed vaccines are available [7]. Monoclonal antibody
treatment (Palivizumab) is efficacious in high-risk infants [8], but the cost-effectiveness of this
approach is under debate [9].
S. pneumoniae and HRSV occupy the same niche: pneumococcus colonizes the nasophar-
ynx, where HRSV infects ciliated epithelial cells. In addition, peak prevalence of disease burden
for both occurs in winter [10, 11], transmission occurs via direct contact and therefore crowd-
ing (e.g. in day care centers) contributes to spread of both pneumococci and HRSV [12–14].
Furthermore, risk factors for development of severe disease are highly similar for both patho-
gens, including premature birth, congenital heart disease, chronic lung disease and high age
[13].
Several studies have described interactions between S. pneumoniae and HRSV [15–17]. Fol-
lowing the discovery of HRSV in 1956, it was described that pneumococci could be cultured
from an HRSV-infected infant [18]. In vitro experiments showed that S. pneumoniae adheres
to HRSV-infected human epithelial cells [19], and conversely, HRSV binds directly to pneumo-
cocci [20, 21]. In addition, HRSV infected mice showed significantly higher levels of pneumo-
coccal bacteremia than controls [20]. Collectively these data suggest that HRSV infection can
predispose individuals to bacterial superinfection, potentially leading to increased morbidity
and mortality.
It has also been suggested that bacterial colonization may enhance respiratory virus infec-
tions. A potential mechanism was shown previously by synthetic bacterial lipopeptides-mediat-
ed enhancement of HRSV infection [22]. Pre-incubation of well-differentiated normal human
bronchial epithelial (wd-NHBE) cells with S. pneumoniae enhanced human metapneumovirus
(HMPV) infection [23]. In addition, frequent nasopharyngeal carriage of pneumococci in chil-
dren under 2 years of age was associated with increased seroconversion rates to HMPV [23].
Moreover, in a clinical trial pneumococcal vaccination reduced the incidence of hospitalization
for pneumonia associated with HRSV by 32% [24]. These observations indicate that pneumo-
coccus and HRSV potentially have bidirectional interactions.
The aim of the current study was to assess the influence of pneumococcal colonization on
subsequent HRSV infection using in vitro and in vivomodels. We used wd-NHBE cells for in
vitro studies and cotton rats (Sigmodon hispidus) for in vivo studies, as the most susceptible
and disease-relevant HRSV model systems currently available. S. pneumoniae isolates had pre-
viously been obtained from nasopharyngeal brushes of healthy infants. One additional S.
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pneumoniae strain was obtained from ATCC. For HRSV infections we used a recently generat-
ed recombinant (r) wild-type subgroup B HRSV strain expressing enhanced fluorescent pro-
tein (EGFP; rHRSVB05EGFP(5)) [25]. We demonstrate that specific strains of S. pneumoniae
can significantly and reproducibly enhance HRSV infection in vitro and/or in vivo.
Materials and Methods
Ethics statement
Animal experiments were conducted in strict accordance with European guidelines (EU direc-
tive on animal testing 86/609/EEC) and Dutch legislation (Experiments on Animals Act,
1997). The protocols were approved by the independent animal experimentation ethical review
committee DCC in Driebergen, The Netherlands (approval number EMC2974). Animal wel-
fare was monitored daily, and animal handling was performed under light anesthesia using
isoflurane.
S. pneumoniae, HRSV and cell culture conditions
Four low passage strains of S. pneumoniae were obtained from nasopharyngeal swabs of chil-
dren under 2 years. Strain 19F was purchased from ATCC (cat. no. 49619). Bacteria were typed
by capsular sequence typing [26, 27]. All strains were penicillin-sensitive, belonged to different
serotypes, and will be referred to by the number of their serotype in this manuscript. Live bac-
terial numbers were determined by optical density at 600 nm and colony forming unit (CFU)
counts obtained from serial dilutions. One day prior to each experiment bacteria were cultured
twice at 35°C (5% CO2 [v/v]) to log phase on trypticase soy agar blood plates with 5% [v/v]
sheep blood (TSA plates, BD). The following day, 12 hours after growth on the second plate
bacteria were harvested in 15 ml tubes and OD600 values were determined. Bacterial suspen-
sions were washed three times with PBS. Low passage (6 and 7) rHRSVB05EGFP(5) had been
generated previously [25]. Virus was grown in HEp-2 cells, and purified by a two-step sucrose
gradient centrifugation. The final stock contained approximately 25% (w/v) sucrose, and had a
titer of 1.3x107 TCID50/ml.
Mycoplasma-free HEp-2 cells (ATCC CCL-23) were grown in DMEM (Lonza) with 10%
(v/v) fetal bovine serum (Sigma-Aldrich). Well-differentiated human normal bronchial epithe-
lial (wd-NHBE, Lonza) cells were grown on air-liquid-interface in filters with 0.4 μm pore size
(Corning) as described previously [23]. Importantly, cells were grown in antibiotics-free medi-
um until after pneumococcus and/or virus inoculation. wd-NHBE cells were used 21 days after
ALI, at which stage beating cilia and mucus production were clearly detectable.
Animals
Four- to five-week-old female cotton rats (Sigmodon hispidus) were obtained from a specific
pathogen-free breeding colony (Harlan). Two or three animals were housed in individual ven-
tilated cages (IVC) supplemented with a tin can as hiding place (height 107 mm, diameter
72 mm) and paper tissues as cage enrichment and received food and water ad libitum. Experi-
ments started after an acclimatization period of 7–10 days.
wd-NHBE cells: co-infection and neuraminidase assays
Bacterial suspensions were prepared as described above. Ratios of bacteria to cells and virus to
cells were 30:1 and 0.4:1, respectively, based on an estimated number of 25,000 cells on the api-
cal surface. The mix (50 μl) was left onto the apical surface for 2 hours at 37°C (5% CO2 [v/v]),
followed by aspiration of the supernatant. Four hours later the apical surface was washed three
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time with Dulbecco’s PBS at 37°C (100 μl) and antibiotics (penicillin (100 U/ml) and strepto-
mycin [100 μg/ml]) were added to the basolateral compartment. Two d.p.i. automated whole
well scans were made, followed by semi-automated enumeration of EGFP+ cells (DotCount,
MIT, Boston).
To study the effect of neuraminidase the apical surface of wd-NHBE cells were treated with
neuraminidase from Vibrio cholerae (Sigma-Aldrich #N7885) at two different concentrations
(30 or 100 mU/ml) for one hour at 37°C. Cells were infected with rHRSVB05EGFP(5) (ratio
0.4:1) after washing the apical surface twice with DPBS. After another four hours wd-NHBE
cells were washed three time and EGFP+ cells were enumerated 2 d.p.i.
Apical inocula of the wd-NHBE coinfection experiments were used to quantify pneumococ-
cal neuraminidase activity using the NA-Star Influenza Neuraminidase Inhibitor Resistance
Detection Kit (Applied Biosystems) according to manufacturer’s protocol. Vibrio cholerae
neuraminidase was used as positive control and reference. Briefly, inocula were diluted 1:5
with NA-Star Buffer and incubated for 20 min with NA-Star chemiluminescent substrate.
Assay plates were placed in a luminometer equipped with an on-board injector (Tecan Infinite
M200). Light signal intensities were measured after injection of accelerator solution.
Infection of colonized animals and in vivo transmission study
Animals were housed in groups of 2 or 3 animals per IVC. After an acclimatization period of
one week, pneumococcal carriage was induced by intra-nasal (i.n.) inoculation of 5x105 CFU
in of PBS (10 μl). Three days later animals were inoculated i.n. with 1x104 TCID50 (10 μl) and
at day eight animals were euthanized by exsanguation. All procedures were performed under
4% (v/v) isoflurane anesthesia. Post-mortem nasopharyngeal lavages and lungs were collected
for isolation of pneumococci and HRSV. Post-mortem nasopharyngeal lavages were obtained
by flushing with virus transport medium (1 ml) without antibiotics from the proximal trachea
towards the nasal cavity. Right lungs were homogenized with a M-tube (GentleMACS, RNA
program 0.10.2) in virus transport medium (2 ml) without antibiotics [28] and centrifuged at
400 × g for 10 min. For determination of bacterial titers S. pneumoniae selective blood agar
plates were custom made (trypticase soy agar blood plates with 5% (v/v) sheep blood and
5 μg/ml gentamycin) [29]. Plates were incubated at 35°C (5% [v/v] CO2) and CFU were
counted manually the next day. Virus isolation from post-mortem nasopharyngeal lavages
was performed as previously described [30, 31]. The lower limit of detection of bacteria was
10 CFU/ml and for HRSV detections in nasopharyngeal lavages or lung homogenates were
30 or 10 TCID50/ml, respectively. Nasal septum, conchae, one agarose-inflated lung were
collected in 2% (w/v) paraformaldehyde for real-time monitoring of EGFP+ cells [28, 32].
Microscopic detection of fluorescence
Microscopically, EGFP+ cells were identified by using an inverted fluorescence microscope
(Zeiss Axiovert 25) or a confocal laser scanning microscope (Zeiss inverted AxioObserver Z1
equipped with LSM 700 scanning module). Nasal septum used for indirect immunofluores-
cence staining was transferred to PBS, permeabilized with 0.1% (v/v) Triton-X100 for 30 min
and subsequently stained. TO-PRO-3 (Invitrogen) was used to counterstain nuclei (red). All
images were generated using Zen 2010 software (Zeiss).
Statistical analysis
All in vitro experiments were performed at least three times using triplicate or quadruple mea-
surements. Statistical analyses were performed with SPSS version 20.0. Mann–Whitney U-tests
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were used to compare differences. A two-sided p-value 0.05 was considered statistically
significant.
Results
Specific S. pneumoniae strains enhance HRSV infection in vitro
We used wd-NHBE cells grown on air-liquid interface expressing beating cilia and goblet cells
as the best available in vitromodel for HRSV infection. Also, we used rHRSVB05EGFP(5),
which is the first HRSV strain displaying the full phenotype and genetic background of cur-
rently circulating wild-type viruses [25]. Along these primary cells and recombinant virus low
passage pneumococci were used to mimic the complex interplay between pneumococcus and
HRSV. Initially the apical surface of wd-NHBE was incubated with S. pneumoniae, but epithe-
lia cultured without antibiotics rapidly deteriorated and died. Therefore, we used an alternative
approach, in which wd-NHBE cells were incubated with a mixture of streptococci and HRSV
in the absence of antibiotics. Virus and bacteria were removed after 2 hours, and 4 hours later
the apical surface was washed with PBS supplemented with antibiotics and the basolateral me-
dium was replaced by medium with antibiotics ensuring survival of the cultures. Co-adminis-
tration of HRSV with three pneumococcus strains (belonging to serotypes 8, 15A and 19F)
resulted in significantly increased numbers of HRSV-infected cells (p<0.05), but two other
strains (belonging to serotypes 19A and 23F) did not modulate HRSV infection (Fig 1A).
A potential role of bacterial neuraminidase?
It was previously described that neuraminidase treatment of HRSV-infected cells enhanced
cell-cell fusion and infection in an epithelial cell line [33]. Thus, we hypothesized that neur-
aminidase could also influence fusion between the viral and host cell membranes. Treatment of
wd-NHBE cells with commercially available bacterial neuraminidase of Vibrio cholerae re-
sulted in a dose-dependent enhancement of HRSV infection (Fig 1B). However, in contrast to
the observations published by Barretto et al., we only observed enhancement of infection when
polarized cells were treated, and inhibition when the virus was pre-treated with neuraminidase
(Fig 1C). To assess the potential role of bacterial neuraminidases in the observed enhancement
of HRSV, we measured the neuraminidase activity of the virus / bacterium mixture after re-
moval from the apical surface of the wd-NHBE cells shown in Fig 1A. However, neuraminidase
activity did not correlate with the observed pattern of enhancement of HRSV infection (Fig
1D).
Streptococcus pneumoniae colonization can enhance HRSV infection in
vivo
In order to extrapolate our in vitro results a new in vivo pneumococcal colonization & HRSV
infection model was developed. We established this model using four S. pneumoniae strains
and the recombinant HRSV strain expressing EGFP (Fig 2A). Animals (n = 6/group) were
intra-nasally inoculated with 5x105 CFU of pneumococci or with PBS as mock control. An in-
oculum volume of 10 μl was used to prevent primary inoculation of the lower respiratory tract
(LRT) [34]. Animals were infected 3 days post-colonization with 1x104 50% tissue culture in-
fectious doses (TCID50) of rHRSV
B05EGFP(5) in PBS (10 μl). No samples were collected until
euthanasia at day 8 (i.e. day 5 after HRSV infection) to prevent any mechanical/physical inter-
ference with bacterial colonization or viral infection and spread. Nasopharyngeal lavages and
lung homogenates were collected post-mortem for isolation of pneumococci and HRSV. Nasal
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septum, conchae and agarose-inflated lungs were collected for immediate monitoring of
EGFP+ cells [28, 32].
Bacteria were re-isolated from nasopharyngeal lavage from all animals intra-nasally inocu-
lated with S. pneumoniae (Fig 2B). The geometric mean titers were about 2x105 CFU/ml, with
the highest variation for strain 8. Bacteria could not be cultured from homogenized lungs of
any of the animals. At the same time point, rHRSVB05EGFP(5) was isolated from nasopharyn-
geal lavages of all animals (Fig 2C). The geometric mean titers were 4.2x103, 1.5x104, 7.4x103,
2.2x104 and 2.0x104 TCID50/ml for the groups receiving mock or strains 8, 15A, 19F and 23F,
respectively. Significantly higher virus loads were detected in groups inoculated with strains
19F and 23F (p<0.05) compared to the mock infection. For the other two strains there ap-
peared to be a trend towards higher HRSV loads, but these did not reach statistical significance.
Furthermore, the variation in virus loads within the colonized groups appeared to be higher.
Upon necropsy, EGFP+ cells were detected in the nasal septum and conchae of all animals.
No differences in numbers of EGFP+ cells were observed between the different groups, al-
though absolute enumeration of these cells was impossible. Syncytia were observed in the nasal
septum and conchae in 5 out of 6 animals of the group inoculated with S. pneumoniae strain
19F as compared to 1 out of 6 animals of the mock group (p<0.05, Fig 3). In the groups that
had received S. pneumoniae strains 8, 15A or 23F these were seen in 1, 1 and 3 animals, respec-
tively (not significantly different from the mock control). A small number of EGFP+ cells was
found in the lungs in two animals that had received S. pneumoniae 19F or 23F (data not
shown).
Cotton rat transmission study
S. pneumoniae strain 19F had enhanced HRSV infection both in vitro and in vivo. We hypothe-
sized that higher virus loads could facilitate transmission of virus or bacteria to naive cage
mates by direct contact. To test this hypothesis, and confirm the pneumococcal enhancement
of HRSV infection in vivo, we designed a transmission experiment in cotton rats (Fig 4A). Two
groups of index animals (n = 6) were mock-treated or intra-nasally inoculated with S. pneumo-
niae strain 19F, with each animal being housed solitarily. Three days later all index animals
were infected intra-nasally with rHRSVB05EGFP(5). At day 5 naive contact animals were
added to each cage permitting direct physical contact between the index and contact animals
for 72 hours, including the anticipated peak of HRSV replication in the index animals. Index
and contact animals were euthanized at days 8 and 11, respectively (Fig 4A). Bacterial and viral
loads were determined in nasopharyngeal lavages and lung homogenates. In the colonized
index group S. pneumoniae was cultured from the nasopharyngeal lavage of all animals, with a
geometric mean titer of 2.1x105 CFU/ml (Fig 4B). In addition, significantly higher virus loads
were detected in the colonized index animals as compared to the mock control index animals
Fig 1. Enhancement of HRSV infection mediated by specific S. pneumoniae strains in wd-NHBE cells.
(A) wd-NHBE cells were inoculated with HRSV and one S. pneumoniae strain with mock control. Strain 8,
15A and 19F enhanced HRSV infection as evidenced by quantification of EGFP+ cells 2 d.p.i. Data are
represented as mean ± SD. * p 0.05; 2-tailed Mann-Whitney U test. (B) wd-NHBE cells were treated with
neuraminidase from Vibrio cholerae, followed by HRSV infection after washing. Two dpi the numbers of
HRSV-infected cells were enumerated. Data are presented as means ± SD. * p 0.05; 2-tailed Mann-
WhitneyU test. (C) HRSV was treated with neuraminidase from Vibrio cholerae before inoculation of wd-
NHBE cells. Treated virus was incubated for 1 hour, followed by washing. HRSV-infected cells were
enumerated 2 dpi. Data are presented as means ± SD. * p 0.05; 2-tailed Mann-Whitney U test. (D) Apical
inocula of the wd-NHBE cell co-infection experiment shown in Fig 1A were tested for neuraminidase activity
using the NA-Star Influenza Neuraminidase Inhibitor Resistance Detection Kit (Applied Biosystems).
Numbers correspond to Vibrio cholerae μU neuraminidase activity. Data are presented as means ± SD.
doi:10.1371/journal.pone.0127098.g001
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Fig 2. Bacterial and virus titers of HRSV infected S. pneumoniae colonized cotton rats. (A)
Experimental design. Pneumococcal carriage was induced by i.n. inoculation of cotton rats with 5x105 CFU
S. pneumoniae in 10 μl at day 0. Three days later animals were infected with 1x104 TCID50 rHRSV
B05EGFP
(5) in PBS (10 μl). At day 8 animals were euthanized. (B) Bacterial titers eight days after induction of
pneumococcal carriage. The geometric mean titer was about 2x105 CFU/ml for the different strains. Data
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(Fig 4C; p<0.05). On day 11 all contact animals were euthanized, and bacterial culture and
HRSV re-isolation procedures were repeated. However, no S. pneumoniae or HRSV was de-
tected in either the nose or the lungs of any of these animals (Fig 4C). Thus, in vivo enhance-
ment of HRSV infection by nasal colonization of cotton rats with S. pneumoniae strain 19F
proved to be reproducible, but we could not detect bacterial or viral transmission.
Discussion
We have shown that specific S. pneumoniae strains enhance HRSV infections both in vitro and
in vivo. In wd-NHBE cells simultaneously inoculated with HRSV and pneumococcus strain 8,
15A or 19F, but not strain 19A and 23F, significantly higher numbers of HRSV-infected epithe-
lial cells. In cotton rats intra-nasally colonized with S. pneumoniaeHRSV replicated to higher
titers. However, in this case strains 19F and 23F resulted in enhancement of HRSV infection,
whereas for strains 8 and 15A only a trend towards higher virus loads was detected. Strain 19F
also promoted syncytium formation in the upper respiratory tract.
Co-infections with respiratory viruses and bacteria have been described, although their
number is limited. Two prospective studies showed that 40% of children admitted to the pedi-
atric intensive care unit with severe HRSV disease had a bacterial co-infection in the lower re-
spiratory tract [16, 35, 36]. Similar observations have been described for influenza virus
infections. During the influenza H1N1 pandemic in 1918–1919, an era in which no antibiotics
were available, the majority of deaths was caused by S. pneumoniae, [37, 38]. In the most recent
influenza virus pandemic starting in 2009 co-infection with S. pneumoniae was found to be as-
sociated with severe disease [39]. Diavatopoulos et al. found that influenza virus infection facil-
itated S. pneumoniae transmission and disease in suckling mice [40]. In addition to S.
pneumoniae, Haemophilus influenzae and Staphylococcus aureus were also associated with in-
fluenza virus infection [41].
symbols represent individual animals, bars represent geometric mean titers (GMT) per group. * p 0.05;
2-tailed Mann-Whitney U test. (C) Virus titers five days after HRSV infection. Significantly higher virus load
were detected in groups with nasal carriage of S. pneumoniae strain 19F and 23F compared to mock-treated.
* p 0.05; 2-tailed Mann-Whitney U test.
doi:10.1371/journal.pone.0127098.g002
Fig 3. HRSV infection in nasal septum of a S. pneumoniae colonized cotton rat. Composite microscopic
UV images of the complete nasal septum of a cotton rat 5 d.p.i. showing a representative syncytium in the
middle (scale bar represents 500 μm). The inset is a confocal laser scanning image of the same nasal septum
with nuclei stained with TO-PRO3 (red; scale bar represents 100 μm).
doi:10.1371/journal.pone.0127098.g003
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Fig 4. In vivo transmission study HRSV infection in S. pneumoniae colonized cotton rats. (A)
Schematic representation of the time course of the experiment. Animals were initially housed in pairs. One of
each pair was pneumococcus- or mock-colonized, and infected with HRSV three days later. Another two
days later the matching naive contact animals were added to their cage, reuniting the original pairs. Index and
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Studies on bacterial colonization modulating virus infections are scarce. Sajjan et al reported
thatH. influenzae can potentiate airway epithelial cell responses to rhinovirus by increasing
ICAM-1 and TLR3 expression in vitro [42]. However, these authors used an eight-hour apical
incubation period of wd-NHBE cells, which in our experience can result in a significant reduc-
tion in transepithelial electric resistance. Kuss et al. studied bacterial and viral interactions in
the enteric tract and showed that the intestinal microbiota promoted poliovirus replication and
systemic pathogenesis via binding to bacterial lipopolysaccharide [43]. Previously, we reported
interactions between S. pneumoniae and HMPV infection in vitro and in vivo [23]. Madhi et al.
showed in a large randomized clinical trial that pneumococcal conjugated vaccination reduced
HRSV pneumonia in human immunodeficiency virus (HIV)-1-uninfected children [24]. Inter-
estingly, bacteria can also protect from pneumovirus infections. Nasally administered immu-
nobiotics (immunoregulatory probiotic lactic acid bacteria) differentially modulate respiratory
antiviral immune responses, thereby inducing protection against pneumonia virus of mice or
the closely related HRSV [44, 45].
Our in vitro co-cultures of S. pneumoniae and HRSV in wd-NHBE cells resulted in enhance-
ment of HRSV infection mediated by S. pneumoniae strains belonging to serotypes 8, 15A and
19F, but not by strains belonging to serotypes 19A and 23F. However, since we tested only one
strain of each of these serotypes, we cannot conclude that these differences are serotype-related,
i.e. mediated by capsular structures. We considered a potential role of pneumococcal neur-
aminidases to explain the differences between these strains. Barretto et al. demonstrated that
neuraminidase can enhance HRSV infection [33]. They found that treatment of HRSV with
neuraminidases of different bacteria led to enhancement of infection. Neuraminidases enzy-
matically remove sialic acids, which could result in improved interaction between an HRSV
transmembrane glycoprotein and its cellular receptor. We repeated these studies with
rHRSVB05EGFP(5) in HEp-2 cells, a larynx carcinoma cell line, and confirmed the previously
reported findings (data not shown). However, neuraminidase treatment of rHRSVB05EGFP(5)
resulted in a dose-dependent inhibition of HRSV infection in wd-NHBE cells. In contrast,
neuraminidase treatment of wd-NHBE cells resulted in a dose-dependent enhancement of
HRSV infection. We speculate that this difference is primarily related to the presence of mucus
in wd-NHBE cells. Neuraminidase treatment of the epithelial surface may result in disruption
of the mucus layer [46, 47], while neuraminidase treatment of the virus may result in surface
charge changes that promote HRSV interactions with mucus and inhibit HRSV binding to the
target cells. Conclusive evidence for a potential role of neuraminidase in the infection enhance-
ment could be obtained by testing pneumococcal strains with or without deletions of the neur-
aminidase genes (NanA and NanB) in our assay systems. However, we were unable to perform
these experiments in the current study.
Pneumococcal carriage may have detrimental consequences as the bacterium can spread to
other parts of the human body. Pneumococcal vaccination has been proven effective in pre-
venting colonization [48]. Current vaccines include up to 23 of the most prevalent and disease-
relevant strains [48]. In our study we have used strains 19F and 23F which are included in cur-
rent vaccine formulations, whereas strains 8 and 15A are not. As global prevalence of serotypes
contact animals were euthanized at day 8 or 11, respectively. (B) Bacterial titer of index and contact animals.
The geometric mean titer (GMT) was about 2x105 CFU/ml for the index group, but no bacteria were isolated
in the contact animals. Each data symbol represents one animal, bars represent GMT. (C) Virus titers of
index and contact animals. Significantly higher virus loads were detected in the index group colonized with
strain 19F, as compared to mock-colonized. In both contact groups no virus could be isolated out of the nose
and lungs. * p 0.05; 2-tailed Mann-Whitney U test.
doi:10.1371/journal.pone.0127098.g004
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included in the vaccine diminishes, other serotypes may fill the niche. This phenomenon is
also referred to as serotype replacement [49–51].
In order to study the effect of pneumococcal carriage on HRSV infection we set up a new
pneumococcal colonization & HRSV infection cotton rat model. To our knowledge this is the
first study describing induction of pneumococcal carriage in cotton rats. S. pneumoniae are au-
tolytic at the end of the log-phase, which is caused by the major enzyme Lyt A [52, 53]. There-
fore, demonstration of high pneumococcal loads in nasopharyngeal lavages, but not in lung
homogenates, 8 days after intra-nasal inoculation in 100% of the animals supports efficient
pneumococcal colonization in the URT. Pneumococcal colonization appeared not to be detri-
mental to the animals, as no physical or behavioral signs of disease were observed. Body
weights were minimally affected: all animals gained weight during the experiment but in the
groups colonized with strains 8 and 15A there was a trend towards reduced gain in weights
(data not shown). However, the differences were not significant and these two strains were not
associated with significant enhancement of HRSV infection in vivo.
Interestingly, HRSV titers of mock-treated animals were quite homogeneous. In contrast, in
some of the colonized animals with (enhancing) pneumococcal strains HRSV titers were al-
most 100-fold higher than those in the mock controls. These animals could potentially be con-
sidered as “superspreaders” [54, 55]. However, in this cotton rat model no transmission of
either HRSV or S. pneumoniae could be detected, even when index and contact animals were
housed together in the same cage. None of the animals displayed any clinical signs of HRSV
upper respiratory tract infection such as rhinorrhea, sneezing, or coughing, reducing the
chance of transmission to naive animals. We conclude that this model using adult cotton rats is
not suitable for HRSV transmission studies.
In conclusion, using a new molecular clone of HRSV that mimics current wild-type strains
in the genuine target cells (wd-NHBE) and a new pneumococcal colonization & HRSV infec-
tion animal model we have shown that S. pneumoniaemodulates HRSV infections.
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